Over-expression of tenascin-C in malignant pleural mesothelioma

Histopathology

Volumn 42, Issue 3, 2003, Pages 280-291

  Kaarteenaho Wiik, Riitta ^a   Soini, Y ^a   Pollanen R ^a   Paakko P ^a   Kinnula, V L ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Cytokine; Extracellular matrix; Glycoprotein; Growth factor; Pleura

Indexed keywords

GLYCOPROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SCORING SYSTEM;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM PROTEINS; PLEURAL NEOPLASMS; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

MARTES;

EID: 0037345309     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2003.01568.x     Document Type: Article

References (32)

1. Chiquet-Ehrismann R. Tenascins, a growing family of extra-cellular matrix proteins. Experientia 1995; 51; 853-862.
2. Erickson HP. Tenascin-C, tenascin-R and tenascin-X: a family of talented proteins in search of functions. Curr. Opin. Cell Biol. 1993; 5; 869-876.
3. Vollmer G. Biologic and oncologic implications of tenascin-C/hexabrachion proteins. Crit. Rev. Oncol. Hematol. 1997: 25; 187-210.
4. Chiquet-Ehrismann R, What distinguishes tenascin from fibronectin? FASEB J. 1990: 4; 2598-2604.
5. Koukoulis GK, Gould VE, Bhattacharyya A et al. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications. Hum. Pathol. 1991: 22; 636-643.
6. Borsi L, Carnemolla B, Ponassi M et al. Steady-state levels of different tenascin mRNAs in various normal human tissues. Cell Biol. Int. 1993; 17; 325-329.
7. Kaarteenaho-Wiik R. Kinnula V. Herva R et al. Distribution and mRNA expression of tenascin-C in developing human lung. Am. J. Respir. Cell Mol. Biol. 2001; 25; 341-346.
8. Young SL. Chang LY. Erickson HP. Tenascin-C in rat lung: distribution, ontogeny and role in branching morphogenesis. Dev. Biol. 1994: 161; 615-625.
9. Härkonen E. Virtanen I. Linnala A et al. Modulation of fibronectin and tenascin production in human bronchial epithelial cells by inflammatory cytokines in vitro. Am. J. Respir. Cell Mol. Biol. 1995: 13; 109-115.
10. Kinnula VL, Linnala A. Viitala E et al. Tenascin and fibronectin expression in human mesothelial cells and pleural mesothelioma cell-line cells. Am. J. Respir. Cell. Mol. Biol. 1998; 19; 445-452.
11. Linnala A. Kinnula V. Laitinen LA et al. Transforming growth factor-beta regulates the expression of fibronectin and tenascin in BEAS 2B human bronchial epithelial cells. Am. J. Respir. Cell. Mol. Biol. 1995: 13: 578-585.
12. Laitinen LA. Laitinen A. Altraja A et al. Bronchial biopsy findings in intermittent or 'early' asthma. J. Allergy Clin. Immunol. 1996: 98; S3-S6.
13. Kaarteenaho-Wiik R. Mertaniemi P. Sajanti E et al. Tenascin is increased in epithelial lining fluid in fibrotic lung disorders. Lung 1998; 176; 371-380.
14. Laitinen A. Altraja A. Kampe M et al. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. Am. J. Respir. Crit. Care Med. 1997: 156; 951-958.
15. Kaarteenaho-Wiik R, Tani T. Sormunen R et al. Tenascin immunoreactivity as a prognostic marker in usual interstitial pneumonia. Am. J. Respir. Crit. Care Med. 1996: 154; 511-518.
16. Soini Y. Pääkko P. Nuorva K et al. Tenascin immunoreactivity in lung tumors. Am. J. Clin. Pathol. 1993: 100; 145-150.
17. Upham JW. Garlepp MJ. Musk AW et al. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 1995; 50; 887-893.
18. Garlepp MJ, Leong CC. Biological and immunological aspects of malignant mesothelioma. Eur. Respir. J. 1995: 8; 643-650.
19. Kumar-Singh S, Weyler J, Martin MJ et al. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and 2-, and TGF beta expression. J. Pathol. 1999; 189: 72-78.
20. Ohta Y, Shridhar V, Bright RK et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br. J. Cancer 1999: 81; 54-61.
21. Jahkola T, Toivonen T. Virtanen I et al. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br. J. Cancer 1998; 78; 1507-1513.
22. Pilch H, Schaffer U, Schlenger K et al. Expression of tenascin in human cervical cancer-association of tenascin expression with clinicopathological parameters, Gynecol. Oncol. 1999; 73; 415-421.
23. Travis WD, Colby TV, Corrin B et al. Histological tgping of lung and pleural tumours, 3rd edn. Berlin: Springer-Verlag, 1999.
24. Dail D, Hammar SP, Pulmonary pathology. 2nd edn. New York: Springer-Verlag, 1994.
25. Rosenfeld MA, Siegfried W, Yoshimura K et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252; 431-434.
26. Siri A, Carnemolla B, Saginati M et al. Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies. Nucl. Acids Res. 1991: 19; 525-531.
27. Pääkko P, Nuorva K, Kamel D et al. Evidence by in situ hybridization that c-erb-2 proto-ongogene expression is a marker of malignancy and is expressed in lung adenocarcinomas. Am. J. Respir. Cell. Mol. Biol. 1992: 7; 325-334.
28. Scarpa S, Giuffrida A, Fazi M et al. Migration of mesothelioma cells correlates with histotype-specific synthesis of extracellular matrix. J. Mol. Med. 1999: 4; 67-71.
29. Kaarteenaho-Wiik R, Lakari E. Soini Y et al. Tenascin expression and distribution in pleural inflammatory and fibrotic diseases, J. Histochem. Cytochem. 2000: 48; 1257-1268.
30. Pääkko P. Kaarteenaho-Wiik R, Pöllanen R et al. Tenascin mRNA expression at the loci of recent injury in usual interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2000: 161; 967-972.
31. Iskaros BF. Tanaka KE. Hu X et al. Morphologic pattern of tenascin as a diagnostic biomarker in colon cancer. J. Surg. Oncol. 1997: 64; 98-101.
32. Hanamura N. Yoshida T. Matsumoto E et al. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. Int. J. Cancer 1997: 73; 10-15.